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MaBACKGROUND There is a paucity of randomized clinical trial data on the use of red blood cell (RBC) transfusion in
critically ill patients, speciﬁcally in the setting of cardiac disease.
OBJECTIVES This study examined how hemoglobin (Hgb) level and cardiac disease modify the relationship of RBC
transfusion with hospital mortality. The aim was to estimate the Hgb level threshold below which transfusion would be
associated with reduced hospital mortality.
METHODS We performed secondary data analyses of Veterans Affairs intensive care unit (ICU) episodes across 5 years.
Logistic regression quantiﬁed the effect of transfusion on hospital mortality while adjusting for nadir Hgb level, demo-
graphic characteristics, admission information, comorbid conditions, and ICU admission diagnoses.
RESULTS Among 258,826 ICU episodes, 12.4% involved transfusions. Hospital death occurred in 11.6%. Without
comorbid heart disease, transfusion was associated with decreased adjusted hospital mortality when Hgb was
approximately <7.7 g/dl, but transfusion increased mortality above this Hgb level. Corresponding Hgb level thresholds
were approximately 8.7 g/dl when comorbid heart disease was present and approximately 10 g/dl when the ICU
admission diagnosis was acute myocardial infarction (AMI). Sensitivity analysis using additional adjustment for selected
blood tests in a subgroup of 182,792 ICU episodes lowered these thresholds by approximately 1 g/dl.
CONCLUSIONS Transfusion of critically ill patients was associated with reduced hospital mortality when Hgb level
was <8 to 9 g/dl in the presence of comorbid heart disease. This Hgb level threshold for transfusion was 9 to 10 g/dl
when AMI was the ICU admission diagnosis. (J Am Coll Cardiol 2015;66:2510–8) © 2015 by the American College of
Cardiology Foundation.H emoglobin (Hgb) level thresholds drivered blood cell (RBC) transfusion practicesin critically ill patients, with additional in-
ﬂuence exerted by other patient factors, such as
increased age, severity of illness, gastrointestinal
hemorrhage, comorbid heart disease, and acute
myocardial infarction (AMI) (1–7). Over the past 2 de-
cades, research has led to better understanding of the
extent to which these transfusion thresholds inﬂu-
ence mortality.
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Subsequent observational studies of intensive care
unit (ICU) patients yielded mixed results, with some
demonstrating increased mortality with transfusion,
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included those with cardiac disease, such as those
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
AMI = acute myocardial
infarction
CHF = congestive heart failure
Hgb = hemoglobin
ICU = intensive care unit
RBC = red blood cell
RCT = randomized controlled
trial
VA = Veterans Affairs
J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5 Ding et al.
D E C E M B E R 8 , 2 0 1 5 : 2 5 1 0 – 8 Transfusion of ICU Patients With Cardiac Disease
2511studies, with some showing beneﬁt only when Hgb
was <8 g/dl (12,15–18). In contrast, a recent, pilot
randomized controlled trial (RCT) documented
reduced mortality with a liberal transfusion strategy
in the setting of acute coronary syndrome (ACS) or
stable angina (19). For congestive heart failure (CHF),
the impact of transfusion is even more uncertain (20).
Notably, the American Association of Blood Banks
clinical practice guidelines recommended a restric-
tive transfusion strategy for hospitalized patients
with pre-existing cardiovascular disease for an Hgb
level #8 g/dl, but these guidelines did not recom-
mend a restrictive or liberal transfusion strategy for
hemodynamically stable patients with ACS. No spe-
ciﬁc mention of a suggested strategy for patients with
CHF was made (21).SEE PAGE 2519More recently, an elegant observational study of
approximately 35,000 AMI hospitalizations from 57
centers used propensity score analysis to identify a
subset of patients who were well-matched on 45
variables. In this subset, transfusion was associated
with a 25% reduction in the odds of hospital mortality
(22). However, the accompanying editorial cautioned,
that despite several observational studies on trans-
fusion in patients with signiﬁcant cardiac disease,
there is still uncertainty on when to transfuse these
patients (23). Nonetheless, there is arguably accu-
mulating evidence that suggests that a restrictive
transfusion strategy may not be optimal in this
setting (13,14,19,22). Although another recent edito-
rial echoed the sentiment that evidence on appro-
priate transfusion thresholds for patients with ACS is
weak, the possibility was entertained that such pa-
tients may yet beneﬁt from transfusion at higher Hgb
levels (e.g., 9 to 10 g/dl) (24).
Due to this ongoing debate, we conducted addi-
tional analyses of a previously developed dataset to
determine how Hgb level modiﬁes the treatment ef-
fect of RBC transfusion during ICU admissions with
respect to hospital mortality in the context of cardiac
disease. Speciﬁcally, we sought to estimate the Hgb
level below which transfusion is associated with
reduced hospital mortality (or transfusion threshold)
across key cardiac conditions, such as comorbid heart
disease, AMI, unstable angina, and CHF. We hypo-
thesized that transfusion thresholds with these
conditions are higher than those advocated in the
restrictive transfusion strategy. Ultimately, our goal
was to assemble additional evidence to assist physi-
cians in deciding when to transfuse critically ill pa-
tients with cardiac disease while we await the results
of deﬁnitive clinical trials.METHODS
We performed secondary analyses of Ve-
terans Affairs (VA) electronic databases at
the Center for Healthcare Organization and
Implementation Research. Ethical approval
was obtained from the VA Bedford Institu-
tional Review Board. Individual-level data on
VA ICU admissions during ﬁscal years 2001
through 2005 were extracted from national-
level VA databases. For hospitals with sepa-
rate surgical and neurological ICUs, we only
selected medical ICU episodes. We excluded
operative cases with surgical admitting
diagnoses. Only the ﬁrst ICU episode of each year
for unique patients was included.
Hospital death was the outcome of interest,
whereas RBC transfusion during the ﬁrst 30 days
of ICU admission was the treatment of interest.
Transfusion receipt was deﬁned as having an Inter-
national Classiﬁcation of Diseases-9th Revision-
Clinical Modiﬁcation (ICD-9-CM) procedure code of
99.04 (transfusion of packed cells) or 99.03 (trans-
fusion of whole blood) in the ICU ﬁle. ICU admis-
sions with at least 1 transfusion documented during
the ﬁrst 30 days were collectively assigned as the
“transfusion” group; all others were included in the
“no transfusion” group. To exclude hospitals that
were possible outliers in terms of transfusion prac-
tices, we arbitrarily removed data from 8 of 120
hospitals where transfusion rates were >2 SD from
the mean.
To specify the nadir Hgb level, we selected the
lowest value during ICU admission before blood
transfusion. If not transfused, we selected the lowest
value during the ﬁrst 30 days of ICU admission. If
none was available, we used the lowest value during
hospital admission before ICU admission.
Other explanatory variables included demographic
characteristics, admission-related information, co-
morbid conditions (e.g., Elixhauser comorbidity
measures [25], Acute Physiology and Chronic Health
Evaluation III chronic health parameters [26], and
others [27,28]), ICU admission diagnoses categories
(adapted from the Healthcare Cost and Utilization
Project) (29), and selected blood test values. Comor-
bid conditions were assigned if their codes were
stated at least once in administrative records during
the previous 2 years, but not where there was an
overlapping admission diagnosis (27). ICU admission
diagnoses were deﬁned by the ﬁrst ICD-9-CM code
from ICU ﬁles. Chronic kidney disease was deﬁned as
a glomerular ﬁltration rate <60 ml/min/1.73 m2 for at
least 3 months (30).
TABLE 1 Patient Characteristics
Explanatory Variables
All
(N ¼ 258,826)
Died in Hospital
Yes
(n ¼ 30,086)
No
(n ¼ 228,740)
Mean hemoglobin level, g/dl 11.4  2.6 9.8  2.4 11.7  2.6
Demographic features
Mean age, yrs 66.1  12.5 70.8  11.7 65.5  12.5
Male 251,596 (97.2) 29,552 (98.2) 222,044 (97.1)
Race
White 162,262 (62.7) 18,644 (62.0) 143,618 (62.8)
Black 43,356 (16.8) 5,205 (17.3) 38,151 (16.7)
Others and unknown 53,208 (20.5) 6,237 (20.7) 46,971 (20.5)
ICU admission-related features
Direct admission 197,336 (76.2) 16,171 (53.7) 181,165 (79.2)
Mean ICU length of stay, days 4.5  6.8 7.8  13.8 4.1  5.0
Chronic kidney disease 57,845 (22.3) 8,864 (29.5) 48,981 (21.4)
Comorbidity groupings
Heart disease 56,555 (21.9) 10,090 (33.5) 46,465 (20.3)
Heart disease risk factors 90,568 (35.0) 12,553 (41.7) 78,015 (34.1)
Neurological disease 15,844 (6.1) 2,657 (8.8) 13,187 (5.8)
Respiratory disease 47,607 (18.4) 7,744 (25.7) 39,863 (17.4)
Liver disease 10,876 (4.2) 2,058 (6.8) 8,816 (3.9)
Psychiatric disease 45,386 (17.5) 5,541 (18.4) 39,845 (17.4)
Coagulopathy 8,389 (3.2) 2,083 (6.9) 6,306 (2.8)
Renal disease 15,666 (6.1) 3,023 (10.0) 12,643 (5.5)
Anemia 34,261 (13.2) 5,998 (19.9) 28,263 (12.4)
Cancer 24,294 (9.4) 5,193 (17.3) 19,101 (8.4)
Peptic ulcer disease 5,272 (2.0) 763 (2.5) 4,509 (2.0)
Endocrine disease 9,134 (3.5) 1,443 (4.8) 7,691 (3.4)
Rheumatological disease 2,984 (1.2) 505 (1.7) 2,479 (1.1)
ICU admission diagnoses
Angina/unstable angina 7,555 (2.9) 81 (0.3) 7,474 (3.3)
Congestive heart failure 14,105 (5.4) 1,533 (5.1) 12,572 (5.5)
Arrhythmia 9,993 (3.9) 528 (1.8) 9,465 (4.1)
Acute myocardial infarction 27,770 (10.7) 2,460 (8.2) 25,310 (11.1)
Other cardiovascular diseases 37,733 (14.6) 1,291 (4.3) 36,442 (15.9)
Peripheral vascular disease 997 (0.4) 152 (0.5) 845 (0.4)
Valvular heart disease 971 (0.4) 91 (0.3) 880 (0.4)
Gastrointestinal bleeding 14,069 (5.4) 997 (3.3) 13,072 (5.7)
Other gastrointestinal disease 8,064 (3.1) 1,283 (4.3) 6,781 (3.0)
Gastrointestinal neoplasm 1,514 (0.6) 422 (1.4) 1,092 (0.5)
Serious neurological disease 8,722 (3.4) 1,650 (5.5) 7,072 (3.1)
Minor neurological disease 598 (0.2) 30 (0.1) 568 (0.2)
Other medical diagnoses 72,821 (28.1) 6,884 (22.9) 65,937 (28.8)
Orthopedic, nonsurgically treated 2,387 (0.9) 320 (1.1) 2,067 (0.9)
Renal disease 6,070 (2.3) 1,083 (3.6) 4,987 (2.2)
Lung neoplasm 1,940 (0.7) 819 (2.7) 1,121 (0.5)
Respiratory arrest/failure 9,881 (3.8) 3,650 (12.1) 6,231 (2.7)
Pneumonia 10,702 (4.1) 2,359 (7.8) 8,343 (3.6)
Chronic obstructive pulmonary disease 8,685 (3.4) 925 (3.1) 7,760 (3.4)
Other respiratory disease 4,342 (1.7) 670 (2.2) 3,672 (1.6)
Infection 9,907 (3.8) 2,858 (9.5) 7,049 (3.1)
Blood transfusion during ﬁrst
30 days of ICU admission
32,097 (12.4) 6,526 (21.7) 25,571 (11.2)
Values are mean  SD or n (%).
ICU ¼ intensive care unit.
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2512STATISTICAL ANALYSES. We used principal com-
ponent analyses to create a smaller number of
comorbidity groupings. This is a data reduction
method that addresses correlation between a set of
observed variables, and it develops a shorter list of
artiﬁcial variables or “principal components” that can
be used in further analyses. Details of the principal
components and their corresponding comorbid con-
ditions are provided in Online Table 1. Logistic
regression was then performed to build explanatory
models for hospital mortality. Blood transfusion
during the ﬁrst 30 days of ICU stay was the treatment
variable. Other aforementioned explanatory vari-
ables, including Hgb, were included. To examine the
effect modiﬁcation of Hgb, comorbid heart disease,
and ICU admission for AMI, unstable angina, and CHF
on the relationship between transfusion and hospital
mortality, we included corresponding interaction
variables. To address clustering of admissions within
ﬁscal years, we employed ﬁxed effects for year as
dummy variables. To understand how absolute hos-
pital mortality rates with and without transfusion
varied with Hgb, we computed model-predicted
mortality rates at different Hgb values from 6 to 11
g/dl. Finally, we conducted sensitivity analyses by
including selected blood tests, namely blood urea
nitrogen, blood total white blood cell, serum albumin,
and serum creatinine as explanatory variables for a
subset of ICU episodes that had complete data on
these investigations. SAS version 9.3 (SAS Institute,
Cary, North Carolina) was used for all data analyses.
RESULTS
Among 258,826 ICU episodes, hospital death occurred
in 30,086 patients (11.6%). Transfusion was docu-
mented in 32,097 (12.4%) episodes during the ﬁrst
30 days of ICU admission. Patient characteristics for
these episodes are shown in Table 1. For 182,792 ICU
episodes with complete information on selected
blood tests, hospital death occurred in 13%, with
transfusion received by 14% during the ﬁrst 30 days
of ICU stay. There were no major differences from the
study population as a whole (Online Table 2). As ex-
pected, patients who died in hospital were older, had
lower Hgb, were more likely to have heart disease and
most other comorbidities, and stayed longer in the
ICU. Notably, those who died were almost twice as
likely to have received transfusion during the ﬁrst
30 days of ICU admission.
Details of logistic regression analyses for hospital
mortality are provided in Online Table 3. The most
important results are those that show the interactions
of blood transfusion with Hgb and cardiac disease.
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2513For the whole group, the odds ratio (OR) for the
interaction between blood transfusion and Hgb was
1.22 (95% conﬁdence interval [CI]: 1.20 to 1.25). This
indicates that for each 1 g/dl increase in Hgb, trans-
fusion was associated with a 22% increase in odds of
hospital mortality. Lower hospital mortality was
associated with transfusion at lower Hgb levels. Cor-
responding ORs for interactions with comorbid heart
disease and ICU admission diagnosis of AMI were 0.82
(95% CI: 0.76 to 0.88) and 0.78 (95% CI: 0.69 to 0.88),
respectively. The interpretation was that transfusion
was associated with lower hospital mortality when
these 2 conditions were present. In other words, for
any given Hgb, the beneﬁt associated with trans-
fusion was greater when patients had comorbid heart
disease or were admitted to the ICU for AMI. The in-
teractions for transfusion with ICU admission for
unstable angina and CHF were not signiﬁcant.
This suggests no differences in beneﬁt with trans-
fusion whether or not these 2 conditions were pre-
sent. The model c-statistic of 0.81 indicates good
model discrimination.
For model-predicted hospital mortality rates with
and without transfusion at different Hgb levels from 6
to 11 g/dl for 3 key permutations of comorbidity and
ICU admitting diagnosis, Figures 1A to 1C (unbroken
blue and orange lines) represent point estimates of
predicted probability of hospital mortality with and
without transfusion, respectively. The corresponding
broken lines represent the 95% CIs for those point
estimates. Conﬁdence bands around these point es-
timates for mortality range from approximately 0.02
to 0.06. As expected, mortality decreased with higher
Hgb for both transfused and nontransfused patients.
However, this decrease was predicted to be steeper
for those who were not transfused. In patients
without comorbid heart disease and who were
admitted to the ICU for a set of reference noncardiac
diagnoses, mortality was lower with transfusion
compared with no transfusion below an Hgb of
approximately 7.7 g/dl, but mortality was higher
above that cutpoint. We can infer that the critical
point at which the risk–beneﬁt balance of transfusion
reversed was at an Hgb in the region of 7.7 g/dl.
However, for those with comorbid heart disease
admitted to the ICU for these noncardiac diagnoses,
mortality was lower with transfusions below an Hgb
of approximately 8.7 g/dl, but mortality was higher
above this level. This indicates that the correspond-
ing critical point was in this region of Hgb level.
Finally, for those with comorbid heart disease who
were admitted to the ICU for AMI, mortality was
lower with transfusion below an Hgb of approxi-
mately 10 g/dl, but was higher above this level, whichwas the critical point for reversal of the risk–beneﬁt
balance.
Beyond obtaining point estimates of the transfusion
threshold, having a sense of the uncertainty of these
estimates would be helpful. The broken line repre-
senting the lower limit of the 95%CI for the transfusion
group (blue line) intersects with that of the corre-
sponding upper limit for the no transfusion group
(orange lines) at Hgb levels of approximately 0.7 to
0.9 g/dl above the transition point across all graphs.
Correspondingly, the broken line representing the
upper limit of the 95% CI for the transfusion group
(blue lines) and that of the corresponding lower limit
for the no transfusion group (orange lines) intersect at
Hgb levels approximately 0.7 to 0.9 g/dl below the
transition point. These values represent worst-case
scenarios with respect to uncertainty around our
estimates of the transition point. In other words, the
true transition point is very likely within the range of
0.7 to 0.9 g/dl below and above our point estimates.
Sensitivity analyses using additional blood test
information on a smaller subset of patients yielded
interaction effects in the same direction. However,
the interaction of transfusion with ICU admission for
AMI was not signiﬁcant (third column of Online
Table 3). Most importantly, the corresponding trans-
fusion thresholds were approximately 1 g/dl lower
than those for the whole group, as seen in Online
Figure 1. We also conducted sensitivity analyses
with robust standard error estimation to account for
clustering by facility. However, this made no differ-
ence in the results of estimated effects or statistical
signiﬁcance. Finally, we repeated the regression
models, but with Hgb speciﬁed as 1 g/dl categories
rather than as a continuous variable for both the main
effect and its interaction with transfusion receipt.
The parameter estimates on the logit of hospital
mortality varied in an approximately linear fashion
across Hgb categories, thereby providing justiﬁcation
for specifying Hgb as a continuous variable. Detailed
results are provided in Online Tables 4 and 5, as well
as Online Figure 2.
DISCUSSION
This is the largest observational study of critically ill
patients to examine the association of blood trans-
fusions with mortality and effect modiﬁcation by Hgb
level and cardiac disease. Our premise is that Hgb
levels exist below which the transfusion risk–beneﬁt
balance reverses (31). Combining our primary results
and those of sensitivity analyses, we infer that the
Hgb level below which transfusion was associated
with reduced hospital mortality or transfusion
FIGURE 1 Model-Predicted Probability of Hospital Mortality
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Hospital mortality with and without transfusion across nadir hemoglobin (Hgb) levels for the whole study population of Veterans Affairs intensive care
unit (ICU) episodes (n ¼ 258,826) was analyzed for a 60-year-old man transferred to the ICU and who stayed for 30 days in ﬁscal year 2005 in the setting
of (A) no comorbid heart disease admitted to ICU for reference medical diagnoses, (B) comorbid heart disease admitted to ICU for reference medical
diagnoses, or (C) comorbid heart disease admitted to ICU for acute myocardial infarction. Orange lines, no transfusion; blue lines, transfusion; unbroken
lines, point estimates; broken lines, 95% conﬁdence limits.
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2514threshold is approximately 7 to 8 g/dl across a het-
erogeneous population of VA ICU patients. Interest-
ingly, these results approximate those of TRICC and
are consistent with a Cochrane Review based on a
meta-analysis of 19 RCTs that conﬁrmed the associa-
tion of restrictive transfusion strategies with reduced
hospital mortality (32). When we consider the results
of TRICC as offering true estimates of the treatment
effect of transfusions, then the convergence ofﬁndings confers added conﬁdence with respect to
our extended analyses of subgroups with cardiac
disease.
It was recognized quite early that critically ill pa-
tients with cardiovascular disease may require a
different transfusion strategy (33–35). Subsequent
analyses of these patients in TRICC revealed that
among those with severe ischemic heart disease,
the restrictive transfusion group had nonsigniﬁcantly
CENTRAL ILLUSTRATION Varying Red Cell Transfusion Thresholds: Depending on Cardiac Disease for Veterans Affairs’
Intensive Care Unit Episodes
Ding, Y.Y. et al. J Am Coll Cardiol. 2015; 66(22):2510–8.
Nadir hemoglobin level below which red cell transfusion is associated with lower mortality when (A) comorbid heart disease (8 to 9 g/dl) and (B) acute
myocardial infarction (9 to 10 g/dl) are present.
J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5 Ding et al.
D E C E M B E R 8 , 2 0 1 5 : 2 5 1 0 – 8 Transfusion of ICU Patients With Cardiac Disease
2515higher mortality than the liberal transfusion group
(13). In a retrospective study of elderly Medicare pa-
tients with AMI, transfusion was associated with
signiﬁcantly lower 30-day mortality if the hematocrit
at admission was #33% (Hgb 11 g/dl) (14). In a recent
pilot RCT of patients with ACS or stable angina who
underwent cardiac catheterization, 30-day mortality
was lower for the liberal transfusion group compared
with the restrictive transfusion groups (19,36).
Together, these ﬁndings suggest that patients with
cardiac disease could beneﬁt from a more liberal
transfusion strategy.
In contrast, other studies suggest that a restrictive
transfusion strategy might be beneﬁcial. These
include a higher predicted 30-day mortality with
transfusion when the nadir Hgb level was >8 g/dl or
there was an equivalent hematocrit value in the
setting of ACS (15,16,37), and higher hospital mor-
tality with transfusion when Hgb was >7 g/dl in
the presence of cardiovascular comorbidities (12).
The reasons for contrasting effects on mortality
in different studies are probably methodological,
including different trial designs and selection issues
with observational studies and RCTs whereparticipants may not be truly representative of the
population of interest. Inadequate statistical hand-
ling may occur, too, where transfusion operates as a
determinant of predictors of outcomes when not
randomized (38).
In our study, having comorbid heart disease raised
the transfusion threshold by approximately 1 g/dl to
approximately 8 to 9 g/dl (Central Illustration). In
other words, the mortality beneﬁt associated with
transfusion was accrued at slightly higher Hgb levels
in the presence of heart disease. Here, our ﬁndings
are consistent with the recommendations of the
AABB (American Association of Blood Banks).
Beyond that, ICU admission for AMI raises this
threshold by a further 1 g/dl to approximately 9 to
10 g/dl (Central Illustration). Together, our results
provide additional evidence, albeit observational in
nature, to support transfusing critically ill patients
with these cardiac conditions at higher Hgb levels. It
is plausible that increased sensitivity to the adverse
consequences of reduced oxygen delivery with ane-
mia exists in the presence of cardiac disease (23).
Anemia may exacerbate myocardial ischemia and
activate the sympathetic nervous system (39,40).
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2516Furthermore, the ability to increase cardiac output
to compensate for reduced oxygen delivery with
anemia may be reduced with cardiac disease (41).
The impact of these effects may vary across the
spectrum of cardiac disease, with AMI being at its
most severe end. This may explain why transfusions
are associated with reduced mortality at higher Hgb
levels as we traverse across the continuum from no
cardiac disease to comorbid heart disease, and ﬁnally
to AMI. Then again, our ﬁndings do not indicate that
these levels should be modiﬁed for unstable angina
or CHF. However, a national heart failure survey
found a nonsigniﬁcant trend toward lower 30-day
mortality with transfusion among propensity score-
matched patients (20).
Bedside decisions on transfusion attempt to bal-
ance achieving greater oxygen carriage for myocardial
support and minimizing risk of transfusion-related
adverse outcomes, including acute lung injury
(42–47) and secondary bacterial infection (48). It is
plausible that speciﬁc comorbid conditions and acute
illnesses could shift this balance toward transfusing
more liberally. In this respect, we have demonstrated
the varying effect of transfusion on hospital mortality
across a range of Hgb levels and the effect modiﬁca-
tion by cardiac conditions. The situation becomes
more complicated with multiple concurrent illnesses
as commonly encountered in critically ill patients.
Suggested transfusion thresholds, at best, serve as a
general guide, and physicians should look beyond
them for more complex patients with advanced age,
multimorbidities, or frailty in addition to their car-
diac illnesses. For them, transfusion decisions are
best guided by considered clinical judgment at the
bedside.
STUDY LIMITATIONS. First, as emphasized, this was
an observational study. Selection bias from unac-
counted factors inﬂuencing transfusion receipt may
exist despite our best efforts to include a wide range
of covariates in our risk-adjustment model. Particu-
larly, we did not have data on some aspects of illness
severity, functional status, and do-not-resuscitate
orders. As shown, sensitivity analyses using addi-
tional test information suggest that the Hgb level at
which the risk–beneﬁt associated with transfusion
reverses could be approximately 1 g/dl lower. With
this information, it is quite likely that the true
transfusion threshold lies between these 2 sets of
estimates. In line with this possibility, we adjusted
our study conclusions accordingly. Second, we did
not have VA data on the accuracy of ICD-9-CM codes
for transfusion. External evidence on validity of the
billing for blood transfusion in a non-VA tertiary care
setting hospital indicated favorable sensitivity andspeciﬁcity for transfusion identiﬁcation from blood
bank records using relevant ICD-9-CM procedure
codes (49). Third, only approximately 3% of our pa-
tients were women. Although there were >7,000 fe-
male ICU admissions, and sex adjustment was made
in regression analyses, we remained cautious on
extrapolating our results to female patients. As such,
our ﬁndings relate largely to critically ill male pa-
tients who have cardiac disease. Finally, data cur-
rency is a potential concern because we used data
from 2001 to 2005. However, it is debatable as to
whether transfusion and ICU practice have changed
enough over the past decade to expect important
differences in our results if we had used more recent
VA data. Although possible, we are of the opinion
that such differences are less likely to be operant.
Despite these limitations, we believe that this study
contributes to the ongoing debate on when critically
ill patients with anemia and cardiac disease should
be transfused. Building on previous work such as the
recent study on transfusion in the setting of AMI by
Salisbury et al. (22), our ﬁndings suggest that the
restrictive transfusion strategy may not be optimal
for patients with selected cardiac conditions. Rather,
they support setting transfusion thresholds at
Hgb levels 1 to 2 g/dl higher when comorbid heart
disease or AMI occur, but not when unstable angina
or CHF do.
CONCLUSIONS
RBC transfusion during ICU admission is associated
with reduced hospital mortality when pre-transfusion
Hgb levels were <8 to 9 g/dl in the setting of comor-
bid heart disease. The transfusion threshold is raised
to 9 to 10 g/dl if the ICU admission is for AMI,
but not for patients with unstable angina or CHF.
Although we are waiting for more deﬁnitive evidence
from randomized clinical trials, these ﬁndings offer
possible interim guidance for physicians on trans-
fusing ICU patients with cardiac disease.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Although transfusion decisions should
be individualized based on clinical assessment, critically ill
patients with comorbid heart disease may beneﬁt from
Hgb levels >8 to 9 g/dl, and patients with ACS may need
levels >9 to 10 g/dl.
TRANSLATIONAL OUTLOOK: Randomized trials
are necessary to determine the Hgb thresholds for
transfusion associated with survival beneﬁt in criti-
cally ill patients with heart disease, including those
with acute coronary syndromes or decompensated
heart failure.
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